Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 62, Issue 1, 2010, Pages 143-149

  Von Delwig, Alexei ^a   Locke, James ^a   Robinson, John H ^a   Ng, Wan Fai ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AUTOANTIGEN; BIOLOGICAL MARKER; CITRULLINE; EPITOPE; THYMIDINE;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; TH17 CELL;

AGGRECANS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CITRULLINE; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; PEPTIDE FRAGMENTS;

EID: 74849112402     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25064     Document Type: Article

References (16)

1. Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the "altered self." Rheumatology (Oxford) 2008;47:567-71.
2. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75.
3. Uysal H, Bockermann R, Nandakumar KS, Sehnert B, Bajtner E, Engstrom A, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009;206:449-62.
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
5. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
6. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
7. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
8. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, Ioan-Facsinay A, Drijfhout JW, van Tol MJ, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808.
9. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.
10. Hill JA, Bell DA, Brintnell WC, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008;205:967-79.
11. Buzas EI, Mikecz K, Brennan FR, Glant TT. Mediators and autopathogenic effector cells in proteoglycan-induced arthritic and clinically asymptomatic BALB/c mice. Cell Immunol 1994;158:292-304.
12. Guerassimov A, Zhang Y, Banerjee S, Cartman A, Leroux JY, Rosenberg LC, et al. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis Rheum 1998;41:1019-25.
13. Buzas EI, Vegvari A, Murad YM, Finnegan A, Mikecz K, Glant TT. T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis. Cell Immunol 2005;235:98-108.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 2003;42:846-55.
16. Boots AM, Verheijden GF, Schoningh R, van Staveren CJ, Bos E, Elewaut D, et al. Selection of self-reactive peptides within human aggrecan by use of a HLA-DRB1*0401 peptide binding motif. J Autoimmun 1997;10:569-78.